NC Republicans file transgender bathroom bill; NC Democrats seek reproductive and LGBTQ+ protections
RALEIGH, N.C. (WNCN) — North Carolina Democrats filed a slew of bills Tuesday all centered around reproductive health and LGBTQ+ protections.
According to Democratic lawmakers, some of the bills will guarantee the rights to use contraception to prevent pregnancy and access fertility treatments through IVF. Others will ban conversion therapy and the use/perception of gender and sexual orientation as a defense in assault and homicide cases. An equality for all bill is also proposed.
'We need to be done with treating people as anything less than full human beings deserving of respect and dignity,' state Sen. Julie Mayfield said.
State Sen. Sophia Chitlik said, 'Contraception is taken to support people with a variety of health challenges, including polycystic ovary syndrome.'
While state Democrats said they're pushing their priorities, Republicans filed Senate Bill 516 Tuesday. Entitled the Women's Safety and Protection Act, it is sweeping legislation that would limit a transgender person's access to bathrooms and their ability to change legal documents.
Republicans have previously said banning biological men from women's bathrooms is a safety measure.
According to Democrats, Republicans are only attacking marginalized communities and putting LGBTQ+ and transgender communities in danger.
'If you don't believe it, just look out there at all those people who just want to be recognized as humans,' state Rep. Allison Dahle said. 'They don't care if you recognize their pronouns, they just want to be human and live their lives.'
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
UPI
30 minutes ago
- UPI
On This Day, June 2: U.S. F-16 shot down over Bosnia O'Grady rescued
1 of 6 | Capt. Scott O'Grady gives a press conference on June 10, 1995, eight days after his F-16 Fighting Falcon was shot down over Bosnia. After six days of evasion, he was rescued by U.S. Marines from the 24th Marine Expeditionary Unit. File Photo by SRA Tana R. Hamilton/ U.S. National Archives On this date in history: In 1865, the Civil War officially came to an end when Confederate Gen. Edmund Kirby Smith, commander of Confederate forces west of the Mississippi, signed the surrender terms offered by Union negotiators. In 1886, U.S. President Grover Cleveland, 49, married Frances Folsom, the 21-year-old daughter of his former law partner, in a White House ceremony. The bride became the youngest first lady in U.S. history. In 1924, President Calvin Coolidge signed the Indian Citizenship Act into law, extending citizenship to all Native Americans born within the United States and its territories. In 1946, in a national referendum, voters in Italy decided the country should become a republic rather than return to a monarchy. The results were officially announced three days later after votes were counted. File Photo by Monika Graff/UPI In 1953, Queen Elizabeth II was crowned in London's Westminster Abbey by the Archbishop of Canterbury. A year earlier, upon receiving word of her father's death, the former Princess Elizabeth broke down and wept. In 1985, police near San Francisco arrested Leonard Lake, who, along with an accomplice, Charles Ng, were accused of between 11 to 25 murders. Lake killed himself in jail before he could go to trial. Ng was convicted in 11 homicides in 1999 and sentenced to death. In 1992, Arkansas Gov. Bill Clinton clinched the Democratic presidential nomination. In 1995, a U.S. F-16 fighter-jet was shot down by a Serb-launched missile while on patrol over Bosnia. The pilot, Air Force Capt. Scott O'Grady, ejected safely and landed behind Serb lines. He was rescued six days later. In 1997, a federal jury in Denver convicted Timothy McVeigh in the 1995 Oklahoma City bombing that killed 168 people. He was sentenced to death and executed June 11, 2001. In 2004, Ken Jennings won his first game on Jeopardy! It started a string that ended after a record 74 wins and more than $2.5 million in winnings. File Photo by Laura Cavanaugh/UPI In 2010, a 52-year-old British taxi driver was accused of a shooting rampage in which 13 people were slain and 11 others injured before he killed himself. In 2014, Seattle's City Council approved a $15 hourly minimum wage -- the highest in the United States. In 2024, Mexicans elect former Mexico City Mayor Claudia Sheinbaum as their first female and first Jewish president. File Photo by Mario Guzman/EPA-EFE
Boston Globe
an hour ago
- Boston Globe
Looking for an edge, Democrats? Just look around you.
Here's a simple, cost-effective, noncontroversial, and human response to the chaos: storytelling. Telling stories about the real-life human consequences of this administration's policies and directives could cut through the noise. Run 15-second spots about real people and their stories nationally across multiple platforms from now to the midterms and beyond. Get The Gavel A weekly SCOTUS explainer newsletter by columnist Kimberly Atkins Stohr. Enter Email Sign Up Hear from a mother returning food when the grocery bill is too high, a student dropping out of college because child care is unavailable or too expensive, a pizza shop owner without a dishwasher, or a contractor who cannot find painters. Watch a parent being arrested by Immigration and Customs Enforcement with their children watching. Show a grandfather waiting hours to talk to Social Security, or a woman taking her medication every other day because health care costs are too high. All in 15 seconds each. Advertisement By telling people about the results of policy decisions and executive actions in clear, simple ways, the Democratic Party can create a groundswell of informed, engaged citizens ready to advocate for change and hold their leaders accountable. It would be powerful. Advertisement Deborah Heller Boston Democrats shouldn't get lost in words A Washington Post report featured in the Globe ('Debate revives over left-wing buzzwords,' Political Notebook, May 27) suggests that terms like 'Food insecurity' sounds like an anxiety disorder. Children in the depths of poverty are not experiencing food insecurity. They are hungry or starving. The Trump regime is not an oligarchy; rather, it is a dictatorship with one ruler enabled by people like Marco Rubio and Mike Johnson, who are not fellow oligarchs but, rather, bootlickers or, to use the fancy Greek word, sycophants. In 'Politics and the English Language,' George Orwell demonstrates how politicians use vague, sugar-coated, euphemistic terms (like 'food insecurity') to justify behavior, policy, or circumstances that cannot be justified. Such words are lies in disguise. Donald Trump's supporters often say they like him because he speaks his mind. He's upfront. He doesn't talk euphemistically, like other politicians. No disguises. Right. He just lies and lies and lies. The mystery is why so many Trump supporters don't seem to care how often or how blatantly he does so. John R. Nelson Gloucester The writer is a professor emeritus of English at North Shore Community College. The poor get poorer while the Trump family gets richer An article on Page A6 of the May 26 Boston Globe was headlined Advertisement The Democrats certainly have to promote a better path forward, but highlighting Trump's abuses while putting forward a plan for the future would be a foundation on which to build. There's so much at stake for the economy, health, education, the environment, and the rule of law that Democrats can champion in contrast to the utter destruction we're seeing now. John Cotter Melrose If populism thrives on grievance, we need a new brand of populism As Larry Edelman and countless other commentators have pointed out, populism thrives on grievance ( We've seen increasing signs of the human tropism toward divisiveness and an 'us against them' mentality. A 'revenge is sweet' refrain now echoes around the world. It's considered not just sweet but justified. Not just justified but necessary. Populism will always thrive on carefully choosing its targets. And though hurting Harvard or immigrants or health research will improve the lives of no one, that doesn't matter. Revenge is rarely rational or well-reasoned. It's emotionally intoxicating. Therein lies the enduring lure of populism. Until the Democrats figure out how to build their own brand of populism, one that captures the hearts, souls, and imaginations of the populace, we will all be forced to endure life in an 'us against them' society. Advertisement Elaine Mintzer Keene, N.H.
Business Upturn
an hour ago
- Business Upturn
Protagonist and Takeda Announce ASCO Plenary Presentation Highlighting Full 32-Week Results from Phase 3 VERIFY Study of Rusfertide, Showing Reductions in Phlebotomy, Improved Hematocrit Control in Polycythemia Vera
Osaka, Japan & Cambridge, Mass., Newark, Calif., United States: Rusfertide plus current standard of care more than doubled clinical response rates across high- and low-risk PV groups, significantly reducing phlebotomy eligibility compared to placebo plus current standard of care, which was the primary endpoint All key secondary endpoints met with statistical significance, including a nearly three-fold reduction in the proportion of patients requiring phlebotomy and a four-fold improvement in hematocrit control in rusfertide arm compared to placebo arm, as well as improvements in patient-reported outcomes No serious adverse events considered related to rusfertide were reported Rusfertide has received Orphan Drug designation and Fast Track designation from the U.S. FDA Protagonist Therapeutics, Inc. ('Protagonist') (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announced detailed results from the Phase 3, randomized, placebo-controlled VERIFY study evaluating rusfertide in patients with polycythemia vera (PV), which met the primary and all key secondary endpoints. The data will be presented as a late-breaking oral presentation at the 61st American Society of Clinical Oncology (ASCO) Annual Meeting Plenary Session (LBA3) at 2:09 pm CDT today. PV is characterized by overproduction of red blood cells (erythrocytosis), which may increase blood viscosity, or thickness, potentially resulting in life threatening thrombotic events such as stroke, deep vein thrombosis and pulmonary embolism. People with PV can experience burdensome symptoms, including severe fatigue, difficulty in concentrating, night sweats and pruritus, which may negatively impact their daily functioning and quality of life. Hematocrit is the ratio of red blood cells to total amount of blood in the body. Achieving and maintaining controlled hematocrit levels of <45% is the primary treatment goal in PV to prevent thrombotic events and alleviate symptoms, but many patients still experience uncontrolled hematocrit levels with current standard of care treatments. Rusfertide, an investigational, first-in-class hepcidin mimetic peptide therapeutic, is under evaluation in the Phase 3 VERIFY study for its potential to regulate iron homeostasis and red blood cell production to control hematocrit levels in patients with PV. In the study, patients dependent on frequent phlebotomy, with or without treatment with cytoreductive therapy, were randomized to receive once-weekly rusfertide or placebo, as an add-on to current standard of care treatment. 'PV poses significant challenges for patients, including debilitating symptoms and the risk of serious thrombotic events, and hematocrit control is crucial to improving patient outcomes. The VERIFY study demonstrated that treatment with rusfertide controls hematocrit levels in phlebotomy-dependent patients, including patients receiving cytoreductive therapies,' said Dr. Andrew T. Kuykendall, M.D., VERIFY Lead Investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. 'These results suggest rusfertide has the potential to become part of the standard of care treatment for patients with PV.' The study met its primary endpoint, which was the proportion of patients achieving a clinical response, defined as the absence of phlebotomy eligibility during study Weeks 20-32. Study results demonstrated 76.9% of patients treated with rusfertide plus current standard of care achieved a clinical response, compared to 32.9% in the placebo plus current standard of care group (p<0.0001).1 The response observed in the rusfertide arm was consistent across subgroups, regardless of risk status or type of concurrent cytoreductive therapy.1 In addition, all key secondary endpoints met statistical significance in favor of the rusfertide arm compared to the placebo arm in the VERIFY study, as follows: The mean number of phlebotomies was 0.5 phlebotomies per patient for those treated with rusfertide plus current standard of care compared to 1.8 phlebotomies per patient for those treated with placebo plus current standard of care during Weeks 0-32 (p<0.0001). 1 Only 27% of patients treated with rusfertide plus current standard of care required phlebotomy between Weeks 0-32, compared to 78% of patients who received placebo plus current standard of care. The mean number of phlebotomies during Weeks 0-32 in the rusfertide arm was reduced across subgroups, including risk status and use of concurrent cytoreductive therapy, versus the placebo arm. 62.6% of patients treated with rusfertide plus current standard of care maintained hematocrit levels below 45% versus 14.4% treated with placebo plus current standard of care (p<0.0001). 1 Rusfertide also showed statistically significant improvements in mean change from baseline to Week 32 in PROMIS Fatigue2 (p<0.03) and the MFSAF Total Symptom Score3 (p<0.03). Rusfertide is the first investigational therapy to prospectively demonstrate a statistically significant improvement in these patient-reported outcomes (PROs) of fatigue and symptom burden in patients with PV.1 Rusfertide was generally well tolerated. The majority of adverse events were low grade and non-serious and no serious adverse events considered related to rusfertide were reported. There was no evidence of increased risk of cancer in patients treated with rusfertide plus current standard of care compared to patients treated with placebo plus current standard of care at the time of the primary analysis. Cancer events were reported in one patient in the rusfertide arm (0.7%) and in seven patients in the placebo arm (4.8%). The most common treatment-emergent adverse events were localized injection site reactions (55.9%), anemia (15.9%) and fatigue (15.2%).1 'These findings underscore rusfertide's potential as a first-in-class erythrocytosis-specific treatment for PV and validate more than a decade of scientific innovation originating from Protagonist's peptide technology platform,' said Dinesh V. Patel, Ph.D., President and Chief Executive Officer at Protagonist. 'We would like to thank all the patients, study staff and investigators for participating in the VERIFY study. We are pleased to partner with Takeda as we continue to advance rusfertide to potentially transform the standard of care in PV patients around the world.' 'These promising pivotal data strongly support rusfertide's potential benefit for a broad spectrum of patients with PV who may be receiving current standard of care therapies but not achieving adequate hematocrit control,' said Phuong Khanh (P.K.) Morrow, M.D., Head of the Oncology Therapeutic Area Unit (OTAU) at Takeda. 'We look forward to receiving additional data from the VERIFY trial later this year, advancing rusfertide towards regulatory approval and continuing our collaboration with Protagonist to bring this innovative therapy to patients.' Rusfertide has received Orphan Drug designation and Fast Track designation from the U.S. Food & Drug Administration (FDA). Takeda Investor Conference Call and Webcast Details Takeda will host an investor call regarding this update on Sunday, June 1, 6-6:45 pm CDT/ 7-7:45 pm EDT / Monday, June 2, 08:00-08:45 (JST). The call will be held using the Zoom platform and Zoom simultaneous interpretation function. Kindly pre-register from the below link: An on-demand replay will be made available on Takeda's website after the conclusion of the event. Protagonist Investor Conference Call and Webcast Details The dial-in numbers for Protagonist's investor update on Monday, June 2nd at 5:00-6:00 am PDT/ 8:00-9:00 am EDT are: US-based Investors: 1-877-300-8521 International Investors: 1-412-317-6026 Conference Call ID: 10199589 The webcast link for the event can be found here: A replay of the presentation will be available on the Protagonist Investor Relations Events and Presentations webpage following the event. About VERIFY The Phase 3 VERIFY study (NCT05210790) is an ongoing, three-part, global, randomized, placebo-controlled study evaluating rusfertide in 293 patients with polycythemia vera over a 156-week period. The study is evaluating the efficacy and safety of once-weekly, subcutaneously self-administered rusfertide in patients with uncontrolled hematocrit who are phlebotomy-dependent despite current standard of care treatment, which could include hydroxyurea, interferon and/or ruxolitinib. The primary endpoint of the study was the proportion of patients achieving a response during Weeks 20-32, which was defined as the absence of 'phlebotomy eligibility.' To meet phlebotomy eligibility, patients in the study were required to have: confirmed hematocrit ≥45% that was ≥3% higher than their baseline hematocrit value, or hematocrit ≥48%. All patients have completed their participation in the randomized, placebo-controlled portion of the study evaluating the efficacy and safety of rusfertide plus current standard of care versus placebo plus current standard of care and are now in the open-label portions of the study. About Protagonist Protagonist Therapeutics is a discovery through late-stage development biopharmaceutical company. Two novel peptides derived from Protagonist's proprietary discovery platform are currently in advanced Phase 3 clinical development, with New Drug Application submissions to the FDA expected in 2025. Icotrokinra (formerly, JNJ-2113) is a first-in-class investigational targeted oral peptide that selectively blocks the Interleukin-23 receptor ('IL-23R') which is licensed to JNJ Innovative Medicines ('JNJ'), formerly Janssen Biotech, Inc. Following icotrokinra's joint discovery by Protagonist and JNJ scientists pursuant to the companies' IL-23R collaboration, Protagonist was primarily responsible for development of icotrokinra through Phase 1, with JNJ assuming responsibility for development in Phase 2 and beyond. Rusfertide, a mimetic of the natural hormone hepcidin, is currently in Phase 3 development for the rare blood disorder polycythemia vera (PV). Rusfertide is being co-developed and will be co-commercialized with Takeda Pharmaceuticals pursuant to a worldwide collaboration and license agreement entered into in 2024 under which the Company remains primarily responsible for development through NDA filing. The Company also has a number of pre-clinical stage oral drug discovery programs addressing clinically and commercially validated targets, including IL-17 oral peptide antagonist PN-881, an oral hepcidin program, and an oral obesity program. More information on Protagonist, its pipeline drug candidates and clinical studies can be found on the Company's website at About Takeda Takeda is focused on creating better health for people and a brighter future for the world. We aim to discover and deliver life-transforming treatments in our core therapeutic and business areas, including gastrointestinal and inflammation, rare diseases, plasma-derived therapies, oncology, neuroscience and vaccines. Together with our partners, we aim to improve the patient experience and advance a new frontier of treatment options through our dynamic and diverse pipeline. As a leading values-based, R&D-driven biopharmaceutical company headquartered in Japan, we are guided by our commitment to patients, our people and the planet. Our employees in approximately 80 countries and regions are driven by our purpose and are grounded in the values that have defined us for more than two centuries. For more information, visit Protagonist Cautionary Note on Forward-Looking Statements This press release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements regarding the potential benefits of rusfertide and the timing of rusfertide regulatory submissions. In some cases, you can identify these statements by forward–looking words such as 'anticipate,' 'believe,' 'may,' 'will,' 'expect,' or the negative or plural of these words or similar expressions. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties that could cause actual results and events to differ materially from those anticipated, including, but not limited to, our ability to develop and commercialize our product candidates, our ability to earn milestone payments under our collaboration agreements with Janssen and Takeda, our ability to use and expand our programs to build a pipeline of product candidates, our ability to obtain and maintain regulatory approval of our product candidates, our ability to operate in a competitive industry and compete successfully against competitors that have greater resources than we do, and our ability to obtain and adequately protect intellectual property rights for our product candidates. Additional information concerning these and other risk factors affecting our business can be found in our periodic filings with the Securities and Exchange Commission, including under the heading 'Risk Factors' contained in our most recently filed periodic reports on Form 10-K and Form 10-Q filed with the Securities and Exchange Commission. Forward-looking statements are not guarantees of future performance, and our actual results of operations, financial condition and liquidity, and the development of the industry in which we operate, may differ materially from the forward-looking statements contained in this press release. Any forward-looking statements that we make in this press release speak only as of the date of this press release. We assume no obligation to update our forward-looking statements, whether as a result of new information, future events or otherwise, after the date of this press release. Takeda Important Notice For the purposes of this notice, 'press release' means this document, any oral presentation, any question and answer session and any written or oral material discussed or distributed by Takeda Pharmaceutical Company Limited ('Takeda') regarding this release. This press release (including any oral briefing and any question-and-answer in connection with it) is not intended to, and does not constitute, represent or form part of any offer, invitation or solicitation of any offer to purchase, otherwise acquire, subscribe for, exchange, sell or otherwise dispose of, any securities or the solicitation of any vote or approval in any jurisdiction. No shares or other securities are being offered to the public by means of this press release. No offering of securities shall be made in the United States except pursuant to registration under the U.S. Securities Act of 1933, as amended, or an exemption therefrom. This press release is being given (together with any further information which may be provided to the recipient) on the condition that it is for use by the recipient for information purposes only (and not for the evaluation of any investment, acquisition, disposal or any other transaction). Any failure to comply with these restrictions may constitute a violation of applicable securities laws. The companies in which Takeda directly and indirectly owns investments are separate entities. In this press release, 'Takeda' is sometimes used for convenience where references are made to Takeda and its subsidiaries in general. Likewise, the words 'we', 'us' and 'our' are also used to refer to subsidiaries in general or to those who work for them. These expressions are also used where no useful purpose is served by identifying the particular company or companies. Takeda Forward-Looking Statements This press release and any materials distributed in connection with this press release may contain forward-looking statements, beliefs or opinions regarding Takeda's future business, future position and results of operations, including estimates, forecasts, targets and plans for Takeda. Without limitation, forward-looking statements often include words such as 'targets', 'plans', 'believes', 'hopes', 'continues', 'expects', 'aims', 'intends', 'ensures', 'will', 'may', 'should', 'would', 'could', 'anticipates', 'estimates', 'projects', 'forecasts', 'outlook' or similar expressions or the negative thereof. These forward-looking statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those expressed or implied by the forward-looking statements: the economic circumstances surrounding Takeda's global business, including general economic conditions in Japan and the United States and with respect to international trade relations; competitive pressures and developments; changes to applicable laws and regulations, including tax, tariff and other trade-related rules; challenges inherent in new product development, including uncertainty of clinical success and decisions of regulatory authorities and the timing thereof; uncertainty of commercial success for new and existing products; manufacturing difficulties or delays; fluctuations in interest and currency exchange rates; claims or concerns regarding the safety or efficacy of marketed products or product candidates; the impact of health crises, like the novel coronavirus pandemic; the success of our environmental sustainability efforts, in enabling us to reduce our greenhouse gas emissions or meet our other environmental goals; the extent to which our efforts to increase efficiency, productivity or cost-savings, such as the integration of digital technologies, including artificial intelligence, in our business or other initiatives to restructure our operations will lead to the expected benefits; and other factors identified in Takeda's most recent Annual Report on Form 20-F and Takeda's other reports filed with the U.S. Securities and Exchange Commission, available on Takeda's website at: or at Takeda does not undertake to update any of the forward-looking statements contained in this press release or any other forward-looking statements it may make, except as required by law or stock exchange rule. Past performance is not an indicator of future results and the results or statements of Takeda in this press release may not be indicative of, and are not an estimate, forecast, guarantee or projection of Takeda's future results. Takeda Medical Information This press release contains information about products that may not be available in all countries, or may be available under different trademarks, for different indications, in different dosages, or in different strengths. Nothing contained herein should be considered a solicitation, promotion or advertisement for any prescription drugs including the ones under development. _____________________________________________________ Kuykendall A et al. Results From VERIFY, a Phase 3, Double-Blind, Placebo (PBO)-Controlled Study of Rusfertide for Treatment of Polycythemia Vera (PV). Oral presentation at: American Society of Clinical Oncology (ASCO) Annual Meeting, June 1, 2025. Chicago, IL. LBA3. PROMIS Fatigue Short Form 8a Total T-Score. MFSAF v4.0 Total Symptom Score 7. View source version on Disclaimer: The above press release comes to you under an arrangement with Business Wire. Business Upturn takes no editorial responsibility for the same.
